Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (12.5 mg, 50 mg, 200 mg) of BI 135585 XX (Tablet) in Chinese and Japanese Healthy Male Volunteers (Randomised, Double-blind,Placebo-controlled Within Dose Groups).
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs BI 135585 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 Feb 2011 New trial record